Bullish Moving Averages
8
Bearish Moving Averages
8
Back Stocks profile
Stock analysis tool for investors
Open an Account with Bigul in 5 minutes
Performance
Today’s low
107.00Today’s High
108.7052W low
97.9052W High
144.30Open Price
107.90Prev. Close
107.1000Volume
53250.00Value
5755260.00Fundamentals
Market Cap Cr
357.60
Price to Earnings
-148.60
Price to Book Value
5.20
Dividend Yield
0.00
PE to Growth
-1.80
Op Revenue TTM Cr
111.19
Net Profit TTM Cr
-2.41
Cash From Operating Activity Cr
1.77
Return on Equity %
-3.65
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
04 Jul, 2024
59.3
Week
59.1
Month
62.5
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
107.93
PIVOT
First Resistance
108.85
Second Resistance
109.62
Third Resistance
110.54
First Support
107.16
Second Support
106.24
Third Support
105.47
Relative Strength Index
47.85
Money Flow Index
55.75
MACD
-0.97
MACD Signal
-1.37
Average True Range
3.81
Average Directional Index
27.45
Rate of Change (21)
6.75
Rate of Change (125)
-12.7
Commodity Channel Index
19.4
Williams %R
-44.4
BETA
1 Month
1.03
3 Month
0.71
1 Year
0.41
3 Year
0.31
PRICE CHANGE ANALYSIS
↑ 0.77%
1 Week
Low
High
105
111.2
↑ 1.34%
1 Month
Low
High
97.9
112
↓ -7.31%
3 Months
Low
High
97.9
134.4
↓ -16.83%
6 Months
Low
High
97.9
144.3
↓ -2.94%
1 Year
Low
High
97.9
144.3
| Indicator | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 27.37 | 31.94 | 27.06 | 21.67 | 20.07 | 18.25 | 23.17 | 22.56 | 28.34 | 28.86 | 65.87 | |
| Operating Expenses Qtr | 24.77 | 25.56 | 22.82 | 18.68 | 16.72 | 14.91 | 17.40 | 15.96 | 16.12 | 16.26 | 20.81 | |
| Operating Profit Qtr | 2.22 | 5.85 | 3.94 | 2.56 | 2.73 | 2.22 | 4.73 | 5.92 | 11.56 | 11.92 | 44.21 | |
| EBIDT Qtr Cr | 2.60 | 6.38 | 4.19 | 2.99 | 3.21 | -3.56 | 5.63 | 6.60 | 9.42 | 12.77 | 43.02 | |
| Depreciation Qtr | 2.77 | 2.72 | 3.46 | 3.34 | 3.32 | 3.33 | 3.46 | 3.41 | 9.13 | 2.12 | 2.09 | |
| Net Profit Qtr | -1.62 | 1.36 | -0.29 | -1.72 | -3.01 | -10.21 | -0.40 | 0.33 | -15.24 | 5.68 | 29.81 | |
| Basic EPS Qtr | -0.50 | 0.40 | -0.10 | -0.54 | -1.05 | -3.57 | -0.15 | 0.11 | -5.32 | 1.97 | 10.38 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 108.04 | 84.04 | 167.07 | 64.47 | 43.34 | |
| Operating Expenses Annual Cr | 91.84 | 64.99 | 66.85 | 47.84 | 43.96 | |
| Operating Profit Annual | 14.56 | 15.60 | 97.50 | 14.43 | -3.22 | |
| Operating Profit Margin Annual % | 13.48 | 18.56 | 58.36 | 22.37 | -7.42 | |
| Total Expenses Annual Cr | 108.92 | 90.08 | 102.16 | 81.44 | 70.74 | |
| EBIDT Annual Cr | 16.21 | 19.05 | 100.22 | 16.64 | -0.62 | |
| EBIDT Annual margin % | 15.00 | 22.67 | 59.99 | 25.80 | -1.43 | |
| Depreciation | 12.29 | 13.52 | 15.39 | 8.05 | 7.77 | |
| PAT Before ExtraOrdinary Items Annual Cr | -2.27 | -13.29 | 39.90 | -14.46 | -55.39 | |
| Net Profit Annual | -2.27 | -13.29 | 39.90 | -14.46 | -55.39 | |
| Basic EPS Annual | -0.72 | -4.65 | 13.87 | -5.08 | -19.48 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 99.33 | 77.50 | 45.22 | 5.12 | 19.42 | |
| Minority Interest Liability Annual Cr | - | - | - | - | - | |
| Total Non Current Liabilities Annual Cr | 50.78 | 71.39 | 69.62 | 163.50 | 146.51 | |
| Total Current Liabilities Annual Cr | 35.78 | 29.97 | 93.68 | 44.75 | 55.34 | |
| Total Capital Plus Liabilities Annual Cr | 185.88 | 178.86 | 208.51 | 213.37 | 221.27 | |
| Fixed Assets Annual | 78.70 | 81.75 | 107.86 | 119.73 | 128.05 | |
| Total Non Current Assets Annual | 136.02 | 136.56 | 160.60 | 187.64 | 190.57 | |
| Total Current Assets Annual | 49.86 | 42.30 | 47.91 | 25.73 | 30.70 | |
| Total Assets Annual | 185.88 | 178.86 | 208.51 | 213.37 | 221.27 | |
| Contingent Liabilities plus Commitments Annual Cr | - | 24.58 | 35.34 | 22.78 | 51.81 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 3.09 | 6.87 | 76.53 | 5.75 | -11.45 | |
| Cash from Investing Activity Annual | -8.61 | 6.77 | -4.33 | 0.13 | 0.13 | |
| Cash from Financing Annual Activity | 2.71 | -20.33 | -63.35 | -7.75 | 19.61 | |
| Net Cash Flow Annual | - | -6.69 | 8.85 | -1.88 | 8.28 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 30.02 | 24.90 | 15.49 | 1.54 | 6.54 | |
| ROE Annual % | -2.28 | -17.38 | 89.79 | -327.92 | -294.93 | |
| ROCE Annual % | 2.61 | 3.71 | 73.87 | 5.09 | -5.05 | |
| Total Debt to Total Equity Annual | 0.57 | 0.92 | 2.87 | 36.39 | 7.22 | |
| EBDIT Annual Margin % | 15.23 | 23.64 | 60.97 | 26.71 | -1.52 |
| Indicator | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 28.06 | 33.11 | 28.23 | 23.25 | 22.67 | 18.88 | 26.72 | 28.21 | 35.72 | 35.98 | 74.57 | |
| Operating Expenses Qtr | 25.74 | 25.70 | 23.81 | 20.23 | 18.94 | 15.60 | 20.50 | 21.19 | 22.58 | 22.55 | 28.26 | |
| Operating Profit Qtr | 2.03 | 6.86 | 4.18 | 2.64 | 3.30 | 2.21 | 5.03 | 6.30 | 12.60 | 13.02 | 45.63 | |
| EBIDT Qtr Cr | 2.34 | 7.41 | 3.99 | 3.02 | 3.31 | -3.73 | 5.97 | 7.25 | 10.33 | 13.60 | 42.42 | |
| Depreciation Qtr | 2.90 | 2.84 | 3.59 | 3.47 | 3.47 | 3.47 | 3.62 | 3.59 | 9.46 | 2.24 | 3.52 | |
| Net Profit Qtr | -2.09 | 2.01 | -0.49 | -1.85 | -3.00 | -10.52 | -0.38 | 0.60 | -15.07 | 6.09 | 28.43 | |
| Basic EPS Qtr | -3.83 | 0.53 | -0.16 | -0.57 | -1.05 | -3.64 | -0.14 | 0.20 | -5.26 | 2.11 | 9.90 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 112.65 | 96.47 | 196.18 | 87.81 | 64.58 | |
| Operating Expenses Annual Cr | 95.48 | 76.23 | 92.94 | 66.57 | 65.16 | |
| Operating Profit Annual | 15.71 | 16.84 | 101.15 | 19.68 | -3.67 | |
| Operating Profit Margin Annual % | 13.95 | 17.46 | 51.56 | 22.42 | -5.68 | |
| Total Expenses Annual Cr | 113.17 | 102.25 | 130.41 | 100.83 | 93.23 | |
| EBIDT Annual Cr | 17.17 | 20.24 | 103.24 | 21.25 | -0.58 | |
| EBIDT Annual margin % | 15.24 | 20.98 | 52.63 | 24.19 | -0.90 | |
| Depreciation | 12.80 | 14.15 | 17.35 | 8.32 | 8.01 | |
| PAT Before ExtraOrdinary Items Annual Cr | -2.62 | -13.15 | 38.44 | -10.09 | -62.62 | |
| Net Profit Annual | -2.49 | -13.21 | 39.00 | -11.55 | -60.54 | |
| Basic EPS Annual | -0.79 | -4.63 | 13.57 | -4.07 | -21.29 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 68.15 | 46.52 | 14.12 | -25.09 | -13.70 | |
| Minority Interest Liability Annual Cr | 0.11 | 0.23 | 0.15 | 0.70 | -0.77 | |
| Total Non Current Liabilities Annual Cr | 50.82 | 72.18 | 71.99 | 165.16 | 148.32 | |
| Total Current Liabilities Annual Cr | 37.64 | 32.60 | 99.35 | 49.24 | 66.32 | |
| Total Capital Plus Liabilities Annual Cr | 156.72 | 151.52 | 185.61 | 190.01 | 200.17 | |
| Fixed Assets Annual | 80.75 | 84.32 | 111.70 | 123.95 | 132.54 | |
| Total Non Current Assets Annual | 106.07 | 107.32 | 133.42 | 160.89 | 164.29 | |
| Total Current Assets Annual | 50.65 | 44.20 | 52.20 | 29.12 | 35.88 | |
| Total Assets Annual | 156.72 | 151.52 | 185.61 | 190.01 | 200.17 | |
| Contingent Liabilities plus Commitments Annual Cr | - | 36.81 | 46.56 | 31.82 | 47.74 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 1.77 | 8.95 | 79.25 | 8.81 | 5.32 | |
| Cash from Investing Activity Annual | -9.49 | 7.35 | -6.17 | -0.16 | -0.11 | |
| Cash from Financing Annual Activity | 1.95 | -21.64 | -63.18 | -11.80 | 3.38 | |
| Net Cash Flow Annual | - | -5.34 | 9.90 | -3.15 | 8.60 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 20.63 | 14.88 | 4.70 | -8.75 | -5.27 | |
| ROE Annual % | -3.65 | -29.07 | 292.38 | 0.00 | 0.00 | |
| ROCE Annual % | 3.66 | 5.12 | 99.57 | 9.17 | -6.41 | |
| Total Debt to Total Equity Annual | 0.84 | 1.55 | 9.66 | -6.24 | -9.75 | |
| EBDIT Annual Margin % | 15.44 | 21.74 | 53.19 | 24.63 | -0.94 |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| KUNAL NARENDRA GANDHI | 6.79 | 75300266 | 0 | 0 |
| NEHAL NARENDRA GANDHI | 6.53 | 75300267 | 0 | 0 |
| PRANAY GODHA | 0.84 | 75300268 | 0 | 0 |
| IPCA LABORATORIES LIMITED | 40.98 | 75300274 | 0 | 30.09 |
| ENAI TRADING AND INVESTMENT PVT. LTD | 2.8 | 75300275 | 0 | 0 |
| Name | Holding Percent | Holding Id |
|---|
| Name | Holding Percent | Holding Id |
|---|---|---|
| THERMO PADS PRIVATE LIMITED | 1.98 | 75300286 |
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|
| Ex-Date | Split Ratio | Record Date |
|---|
| Ex-Date | Purpose | Notes |
|---|---|---|
| May 21, 2024 | Audited Results & Others | To consider other business matters |
| Apr 16, 2024 | Others | inter alia: to allot and issue 26,00,000 Equity Shares upon conversion of 26,00,000 Warrants to Ipca Laboratories Limited, part of a Promoter Group. |
| Feb 08, 2024 | Quarterly Results | - |
| Nov 02, 2023 | Quarterly Results | - |
| Aug 02, 2023 | Quarterly Results | - |
| May 23, 2023 | Audited Results | - |
| Apr 18, 2023 | Others | - |
| Feb 07, 2023 | Quarterly Results | - |
| Jan 21, 2023 | Preferential issue of shares | - |
| Nov 09, 2022 | Quarterly Results | - |
| Aug 08, 2022 | Quarterly Results & Amalgamation | - |
| May 20, 2022 | Audited Results | - |
| Jan 20, 2022 | Quarterly Results | - |
| Oct 29, 2021 | Quarterly Results | - |
| Aug 04, 2021 | Quarterly Results | - |
| Jun 02, 2021 | Audited Results | - |
| Feb 11, 2021 | Quarterly Results | - |
| Nov 06, 2020 | Quarterly Results | - |
| Aug 07, 2020 | Quarterly Results | - |
| Jun 10, 2020 | Audited Results | - |
| Feb 12, 2020 | Quarterly Results | - |
| Jan 13, 2020 | Preferential Issue of shares | inter alia to propose the issue of Shares through preferential basis to the Promoters. |
| Nov 01, 2019 | Quarterly Results | - |
| Aug 09, 2019 | Quarterly Results | - |
| May 18, 2019 | Audited Results | - |
| Feb 12, 2019 | Quarterly Results | - |
| Nov 01, 2018 | Quarterly Results | - |
| Aug 13, 2018 | Quarterly Results & A.G.M. | - |
| May 29, 2018 | Audited Results | - |
| Apr 05, 2018 | Others | Appointed Mr. Dinesh Darji as Company Secretary and Compliance Officer (KMP) of the Company with effect from 6th April, 2018. |
| Feb 12, 2018 | Quarterly Results | - |
| Nov 24, 2017 | Quarterly Results | (Revised) |
| Aug 30, 2017 | Others | - |
| Jul 04, 2017 | Others | To consider Issue of Equity shares/warrants on preferential Basis. |
| May 29, 2017 | Audited Results | - |
| Apr 01, 2017 | Others | Reconsidered the date of merger of Lyka Healthcare Ltd, wholly owned subsidiary with Lyka Labs Ltd |
| Feb 14, 2017 | Quarterly Results | - |
| Nov 05, 2016 | Quarterly Results | - |
| Aug 12, 2016 | Quarterly Results | - |
| May 27, 2016 | Audited Results | - |
| Mar 11, 2016 | Others | To discuss / approve merger of Lyka Healthcare Ltd, a wholly owned subsidiary and Lyka Exports Ltd, a subsidiary with Lyka Labs Ltd. |
| Feb 12, 2016 | Quarterly Results | - |
| Dec 28, 2015 | Others | TO raise funds by issue of securities and take necessary action in this regard. |
| Nov 10, 2015 | Quarterly Results | (Revised from 07/11/2015) |
| Nov 02, 2015 | To consider Allotment of Equity Shares | - |
| Aug 29, 2015 | Audited Results | - |
| Aug 27, 2015 | Others | To LyKa Exports Limited, its subsidiary to sell its Animal Healthcare Division to M/s. Alivira Animal Health Limited, a subsidiary of Sequent Scientific Limited. |
| Aug 11, 2015 | Appointment of Director | - |
| May 15, 2015 | Quarterly Results | - |
| Apr 24, 2015 | Appointment of Independent Director | - |
| Feb 14, 2015 | Quarterly Results | Revised from 12/02/2015 |
| Dec 17, 2014 | Others | To consider issue of further Shares / Warrants / any other securities on Preferential basis to Promoter / Promoter Group / others. |
| Nov 13, 2014 | Quarterly Results | - |
| Aug 28, 2014 | Audited Results | for 15 months ended 30.06.2014 |
| Jul 14, 2014 | Others | 1. Sale of factory at Tarapur. 2. Appointment of Scrutinizer for Postal Ballot. 3. To decide Calendar of Events for Postal Ballot. |
| May 30, 2014 | Audited Results | - |
| Feb 14, 2014 | Quarterly Results | - |
| Nov 14, 2013 | Quarterly Results | (Meeting rescheduled) |
| Aug 14, 2013 | Quarterly Results | - |
| May 30, 2013 | Audited Results | - |
| Feb 14, 2013 | Quarterly Results | - |
| Aug 31, 2012 | Audited Results | (Revised) |
| Aug 14, 2012 | Quarterly Results | - |
| May 15, 2012 | Quarterly Results | - |
| Mar 29, 2012 | Others | The Board has deferred transfer / sale of Company's R&D Division to its wholly owned subsidiary Company. |
| Feb 14, 2012 | Quarterly Results | - |
| Nov 14, 2011 | Quarterly Results | - |
| Aug 12, 2011 | Quarterly Results | - |
| May 14, 2011 | Quarterly Results | (Revised) |
| Mar 25, 2011 | Audited Results | (Revised) |
| Feb 15, 2011 | Quarterly Results | - |
| Nov 15, 2010 | Quarterly Results | - |
| Aug 12, 2010 | Quarterly Results | - |
| May 14, 2010 | Quarterly Results | - |
| Feb 23, 2010 | Audited & Consolidated Qtrly Results | To consider the Consolidated Unaudited Financial Results for the Quarter ended December 31, 2009 & to consider the Audited Annual Accounts for the period of 18 months ended September 30, 2009. |
| Jan 30, 2010 | Quarterly Results | - |
| Oct 30, 2009 | Quarterly Results | - |
| Jul 31, 2009 | Quarterly Results | - |
| Apr 29, 2009 | Quarterly Results | - |
| Jan 30, 2009 | Quarterly Results | - |
| Oct 24, 2008 | Quarterly Results | (Revised) |
| Aug 29, 2008 | Audited Results | - |
| Jul 31, 2008 | Quarterly Results | - |
| Apr 30, 2008 | Quarterly Results | - |
| Jan 31, 2008 | Quarterly Results | - |
| Nov 07, 2007 | Issue of Financial Instruments | A Board Meeting will be held to consider the issue of Financial Instruments on Preferential basis. |
| Oct 31, 2007 | Quarterly Results | - |
| Jul 31, 2007 | Quarterly Results | - |
| Jul 21, 2007 | Audited Results | 18 months |
| Jun 19, 2007 | Issue of Financial Instruments | To consider the issue of Financial Instruments on Preferential basis. |
| Apr 30, 2007 | Quarterly Results | - |
| Jan 31, 2007 | Quarterly Results | - |
| Oct 31, 2006 | Quarterly Results | - |
| Jul 31, 2006 | Quarterly Results | - |
| Apr 29, 2006 | Quarterly Results | - |
| Apr 19, 2006 | Accounts | - |
| Jan 30, 2006 | Issue of financial instruments | May consider the issue of financial instrument on a preferential basis. |
| Dec 30, 2005 | Proposal of investment | To consider the proposal of investment to be made by the company. |
| Nov 16, 2005 | Rights Issue/Preferential Issue | To consider the issue of Financial Instruments on Preferential basis &/or Rights basis. |
| Oct 31, 2005 | Quarterly Results | - |
| Aug 09, 2005 | Quarterly Results & Others | To consider the issue of Non Convertible Cumulative Redeemable Preference Shares on private placement basis. (Revised) |
| May 30, 2005 | Issue of Financial Instruments | To consider the issue of Financial Instruments on Preferential Basis to the Promoters and Business Associates. |
| Apr 30, 2005 | Quarterly Results & Pref. Issue | (Revised) |
| Mar 03, 2005 | Accounts | (Revised) |
| Jan 31, 2005 | Consider the issue of GDRs | - |
| Oct 30, 2004 | Quarterly Results | - |
| Jul 30, 2004 | Quarterly Results | - |
| Apr 30, 2004 | Unaudited Financial Results | - |
| Feb 20, 2004 | Accounts (18 Months) & General | Dicided in principle for the issuance of GDR upto US$ 6,500,000 to partly finance the capital expenditure and working capital requirements. |
| Jan 30, 2004 | Quarterly Results | - |
| Oct 31, 2003 | Quarterly Results | - |
| Sep 26, 2003 | Others | Issue of financial instruments on preferential basis. |
| Jul 31, 2003 | Quarterly Results | - |
| Apr 30, 2003 | Quarterly Results | - |
| Jan 31, 2003 | Quarterly Results | - |
| Oct 31, 2002 | Quarterly Results | - |
| Aug 23, 2002 | Accounts | - |
| Jul 31, 2002 | Quarterly Results | - |
| Apr 30, 2002 | Quarterly Results | - |
| Feb 19, 2002 | Others | Joint venture between Hetero Drugs Ltd. for marketing and distribution of formulation in domestic market. |
| Jan 31, 2002 | Quarterly Results | - |
| Oct 31, 2001 | Quarterly Results | - |
| Jul 31, 2001 | Quarterly Results | - |
| Apr 30, 2001 | Quarterly Results | - |
| Feb 22, 2001 | Accounts | Accounts for the 18 months |
| Jan 31, 2001 | Quarterly Results | - |
| Oct 31, 2000 | Quarterly Results | - |
| Jul 31, 2000 | Quarterly Results | - |
| Apr 29, 2000 | Quarterly Results | - |
| Jan 31, 2000 | Quarterly Results | - |
| Oct 30, 1999 | Quarterly Results | - |
| Aug 24, 1999 | Accounts | - |
| Jul 30, 1999 | Quarterly Results | - |
| Apr 29, 1999 | Quarterly Results | - |
| Jan 30, 1999 | Quarterly Results | - |
| Nov 21, 1998 | Accounts & Dividend | - |
| Oct 31, 1998 | Quarterly Results | - |
| Mar 16, 1998 | Issue of Capital and/or share warrants | - |
| Feb 27, 1998 | Half Yearly Results | - |
| Aug 30, 1997 | Unaudited Financial Results | - |
| Ex-Date | Bonus Ratio | Record Date |
|---|
26 Jun 2024
LYKA LABS LTD. - 500259 - Closure of Trading Window
Pursuant to the the SEBI ( prohibition of Insider Trading) Regulations, 2015; the Company informed closure of trading window closure , as detailed therein.
26 Jun 2024
LYKA LABS LTD. - 500259 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation for loss of share certificate, as detailed therein.
07 Jun 2024
LYKA LABS LTD. - 500259 - Update On The Scheme Of Amalgamation
Updates on the Scheme of Amalgamation for its next hearing is enclosed herewith.
29 May 2024
LYKA LABS LTD. - 500259 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Secretarial Compliance Report for the year ended 31st March 2024, is enclosed
23 May 2024
LYKA LABS LTD. - 500259 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Enclosed standalone and consolidated financial results as published in the newspapers under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
21 May 2024
LYKA LABS LTD. - 500259 - Financial Results For The Year Ended 31.03.2024
Financial Results for the year ended 31.03.2024
21 May 2024
LYKA LABS LTD. - 500259 - Board Meeting Outcome for Outcome Of Board Meeting
Outcome of Board Meeting
15 May 2024
LYKA LABS LTD. - 500259 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificates as per detailed mentioned therein.
15 May 2024
LYKA LABS LTD. - 500259 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of issue of duplicate share certificates with the details mentioned therein.
14 May 2024
LYKA LABS LTD. - 500259 - Update on board meeting
The Board Meeting to be held on 21/05/2024 has been revised to 21/05/2024 Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in continuation to our prior intimations dated 10th May 2024, relating to the Board Meeting scheduled on Tuesday, 21st May 2024, this is to inform you that the said meeting is rescheduled at 03:30 p.m. instead of 12:00 noon, inter alia to consider and approve Audited Standalone and Consolidated Financial Results for the quarter and financial year ended on 31st March 2024.
